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ABSTRACT
To promote expression of endogenous genes ad libi-
tum, we developed a novel, programmable transcrip-
tion factor prototype. Kept together via an MS2 coat
protein/RNA interface, it includes a fixed, polypep-
tidic transactivating domain and a variable RNA do-
main that recognizes the desired gene. Thanks to
this device, we specifically upregulated five genes,
in cell lines and primary cultures of murine pallial
precursors. Gene upregulation was small, however
sufficient to robustly inhibit neuronal differentiation.
The transactivator interacted with target gene chro-
matin via its RNA cofactor. Its activity was restricted
to cells in which the target gene is normally tran-
scribed. Our device might be useful for specific ap-
plications. However for this purpose, it will require
an improvement of its transactivation power as well
as a better characterization of its target specificity
and mechanism of action.
INTRODUCTION
Artificial transactivation of specific endogenous genes ad li-
bitum is a desirable goal for a number of basic and applied
research purposes. This goal has been achieved by short
siRNA/miRNA-like molecules targeting gene promoters
(1–4), termini (5) or enhancers (6). Commonly referred to
as RNA activation, this procedure has been successfully im-
plemented for a large number of genes (7). Its effectors are
expected to destabilize transcription-inhibiting ncRNAs or
ease the recruitment of transcription-promoting complexes
to chromatin (reviewed in (8)). Alternatively, transactiva-
tion of endogenous genes may be obtained by dedicated
artificial enzymes, able to recognize arbitrary target se-
quences by polypeptidic, Zinc finger- (ZF-) type (9–13)
and TransActivator Like Element- (TALE-) type (14–16),
DNA-interacting domains. Albeit nicely working, these en-
zymes may display suboptimal efficiency and/or specificity
of DNA–protein interaction. Large sizes of their DNA-
binding domains may, as well, pose problems of cDNA
synthesis and delivery (17). Recently, the allocation of the
DNA-recognition function to a guide-RNA cofactor, as
implemented in artificial, Clustered Regularly Interspaced
Short Palindromic Repeat (CRISPR)-derived transactiva-
tors (18–23), allowed to solve DNA recognition problems
thanks to a far simplified and straightforward approach.
However, CRISPR molecules are even larger than TALE-
and ZF-transactivators (24).
To address these issues, we have conceived a novel, small
and non-CRISPR-based device. This consists of a fully
synthetic, ribonucleoprotein transcription factor, including
a polypeptidic trans-activating domain as well as a non-
coding RNA ‘bait’ domain. The former stimulates tran-
scription. The latter specifically drives the whole ribonucle-
oprotein to the target gene. The two elements are kept to-
gether by two ancillary domains, a polypeptidicMS2RNA-
interacting domain (25), covalently joined to the former and
forming with it the polypeptidic ‘apo-factor’, and its corre-
sponding hairpin RNA interactor (26,27), covalently joined
to the latter and forming with it the RNA ‘cofactor’.
As a proof of principle, we assessed the feasibility of this
design with three genes highly expressed in HEK293T cells,
FMR1, NAP22 and NRGN. Moreover, we employed this
device to stimulate two transcription factor genes involved
in early cortico-cerebral development, Emx2 and Foxg1.
These genes control pallial field specification (28,29), dic-
tate precursors population kinetics (6,30–34) and modulate
laminar (35,36) as well as areal (37,38) neuronal differentia-
tion. We selected them, because of high responsivity of pro-
liferating pallial precursors to even small changes of their
expression levels (6,39–41), offering an easily detectable bi-
ological readout of the efficacy of our procedure, as well as
because of potential therapeutic interest of their artificial
manipulation (34).
Remarkably, our device upregulated all five selected
genes. Gene upregulation was small, however specific. In
case of cortico-cerebral precursors, it led to a clear reduc-
tion of neuronal differentiation. Notably, the activity of our
device was confined to cells already expressing the gene of
interest (GOI). Finally, performances of our transactivator
could be optimized, by improving key features of its apo-
factor and cofactor components.
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MATERIALS AND METHODS
Animal handling
Wild-type, CD1 strain mice used in this study were pur-
chased from Harlan-Italy and housed at the SISSA mouse
facility. Embryos were staged by timed breeding and vagi-
nal plug inspection. Animals handling and subsequent pro-
cedures were in accordance with European laws [Euro-
peanCommunities Council Directive ofNovember 24, 1986
(86/609/EEC)] and with the National Institutes of Health
guidelines. Embryos (E10.5 and E12.5) were harvested from
pregnant dames killed by cervical dislocation and put in
sterile ice-cold PBS supplemented with 0.6% glucose. Cere-
bral cortices (E12.5), mesencephalons (E10.5) and rhombo-
spinal tracts (E10.5) were then dissected and collected in the
same solution.
Cell culture
Embryonic cortico-cerebral tissue was mechanically disso-
ciated to single cells by gentle pipetting. Neural precursor
cells were subsequently counted in a Burker chamber and
plated in 24-multiwell plates (Falcon), at the density of 1000
cells/l, in a proliferativemedium (DMEM-F12, 1XGluta-
max (Gibco), 1X N2 (Invitrogen), 1 mg/ml BSA, 0.6% glu-
cose, 2 g/ml heparin (Stem Cell Technologies), 20 ng/ml
bFGF (Invitrogen), 20 ng/ml EGF (Invitrogen), 1X Pen-
Strept (Gibco), 10 pg/ml Fungizone (Gibco)). Neural pre-
cursors were acutely infected by recombinant lentiviruses
and kept in culture up to 96 h.
HEK293T cells were cultured in Iscove’s Modified Dul-
becco’s Medium 1X (Gibco) supplemented with 10% FBS
(Sigma). They were used for lentiviral production and titra-
tion as well as for FMR1, NAP22 and NRGR experiments.
Building the NMHV constructs
The codon- and restriction enzyme-optimized coding
sequence (cds) of NMHV (Nuclear-localization-signal,
multimerized-MS2 peptide, Hemagglutinin-antigen,
Virion-peptide-16) apo-transactivator is the following:
ACCATGGTTCCAAAAAAGAAGAGAAAGGTGCC
AAAAAAGAAGAGAAAGGTAGCTTCTAACTTTACT
CAGTTCGTTCTCGTGGAAAATGGCGGAACTGGC
GACGTGACTGTCGCCCCAAGCAACTTCGCTAACG
GGGTCGCTGAATGGATCAGCTCTAACTCGCGTTC
ACAGGCTTACAAAGTAACCTGTAGCGTTCGTCAG
AGCTCTGCGCAGAATCGCAAATACACCATCAAAG
TCGAGGTGCCTAAAGTGGCAACCCAGACTGTTG
GTGGAGAGGAGCTTCCTGTAGCCGGCTGGCGTT
CGTACTTAAATATGGAACTAACCATTCCAATTTTC
GCTACGAATTCCGACTGCGAGCTTATTGTTAAGG
CAATGCAAGGTCTCCTAAAAGATGGAAACCCGA
TTCCCTCAGCAATCGCAGCAAACTCCGGCATCTA
CTATCCGTATGATGTGCCGGATTATGCGACCGGT
GACGCCCTTGACGATTTTGACTTAGACATGCTCC
CAGCCGATGCCCTTGACGACTTTGACCTTGATAT
GCTGCCTGCTGACGCTCTTGACGATTTTGACCTT
GACATGCTCCCAGGCTAA (here, Kozak/start,
NLS(2x), MS2 coat potein, HA tag, AgeI restriction
site, VP16 transactivating peptide (3x) and stop modules
are highlighted by alternate styles, normal and underlined).
NMHV cds was synthesized, cloned into pUC57, grown
in Xl1-blue cells and sequence-verified for us by Gen-
Script. The cds was transferred as BamHI/SalI fragment
into BamHI-SalI cut pCCLsin.PPT.hPGK.EGFP.Wpre
(42). The resulting plasmid, LV NMHV, was subsequently
grown in ElectroMAXTM Stbl 4TM (Invitrogen) cells and
sequence-verified. LV NMHV was used as an expression
plasmid for FMR1, NAP22 and NRGN experiments in
HEK293T cells. The same construct was utilized in produc-
ing the corresponding recombinant lentivirus, forEmx2 and
Foxg1 assays in neural precursors.
Please note that pCCLsin.PPT.hPGK. EGFP.Wpre was
used as the negative control for LV NMHV and is referred
to as ‘EGFP’, unless otherwise indicated.
The NMHE expressing lentivector was obtained from
LV NMHV, replacing its AgeI/SalI fragment (encoding
for the VP16 peptide) by the 141bp AgeI/SalI fragment
ACCGGTTACCTGAGCACCCAGTCCGCCCTGAG
CAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATC
ACTCTCGGCATGGACGAGCTGTACAAGTAAAG
CGGCCGCGTCGAC (encoding for the carboxyterminal
EGFP peptide YLSTQSALSKDPNEKRDHMVLLEF
VTAAGITLGMDELYK).
Building ncRNA constructs
The sequence of the RNA cofactor fragment MF6 was
as follows (‘MS2 coat protein-binding stem-and-loop moi-
eties’ are underlined):
MF6 AGATCTCGGGAAACATGAGGATCACCCA
TGTCGCCCGCTCCACCCAAACAACCCCCTAAACA
TGAGGATCACCCATGTCGAGGGCACCACCCAAA
CAAACAATGAAACATGAGGATCACCCATGTCGC
ATTCTCCAACCAACCAACCGGGGAAACATGAGG
ATCACCCATGTCGCCCCCTACACCCAAACAACCG
CGCAAACATGAGGATCACCCATGTCGCGCGCAT
CACCCAAACAAACCAGGAAACATGAGGATCACC
CATGTCGCCTGGGATCCACCGATATC
MF6 was cloned as BglII/EcoRV fragment into BamHI-
EcoRV cut pcDNA3PvuII, thus obtaining MF6-ø.
FMR1-, NAP22- and NRGN-specific, wild-type ncRNA
baits were amplified from genomic DNA by the oligos re-
ported in Supplementary Table S1. NAP22.60L-derivative,
mutant baits (for sequences, see Supplementary Table S7)
were chemically synthesized as dsDNAs, flanked by sticky,
BamHI/SalI compatible adaptors. All baits were then
cloned as BamHI/XhoI or BamHI/SalI fragments into the
BamHI/XhoI cut MF6-øplasmid, thus obtaining the cor-
responding MF6-bait constructs.
Sequences of the RNA cofactor fragments MF1 and
MF2 were as follows (here ‘MS2 coat protein-binding stem-
and-loop moieties’ are underlined):
MF1 GATCGATATCCGGGAAACATGAGGATCAC
CCATGTCGCCCGCAGCGGATCCCCCGTCGACTTT
TTTGGTACC;
MF2 GATCGATATCCGGGAAACATGAGGATCAC
CCATGTCGCCCGCAGCGGATCGATATCCGGGAA
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ACATGAGGATCACCCATGTCGCCCGCAGCGGAT
CCCCCGTCGACTTTTTTGGTACC.
MF1 was cloned as BamHI-compatible/KpnI fragment
into BamHI-KpnI cut pCCLsin.PPT.hPGK.EGFP.Wpre
vector (42), thus obtaining LV MF1-ø. LV MF2-øwas
obtained by cloning an additional MF1 finger (a BamHI-
compatible/KpnI fragment) into BamHI/KpnI cut
LV MF1-ø.
The Emx2 and FoxG1 ncRNA baits were generally am-
plified from genomic DNA, by the oligos reported in Sup-
plementary Table S2. The Emx2 30bp bait was obtained by
annealing the two oligos reported in the same table. Baits
were cloned as BglII/XhoI fragments into BamHI/SalI cut
LV MF1/2-øplasmids, thus obtaining the corresponding
LV MF1-bait and LV MF2-bait constructs.
Building accessory expression plasmids
Plasmids driving constitutive expression of mCherry
and EGFP referred to in Supplementary Figures S1
and S5, Pgkp1-mCherry and CMVp-EGFP, were ob-
tained by replacing EGFP cds by mCherry cds in pC-
CLsin.PPT.hPGK.EGFP.Wpre and by cloning EGFP cds
into pcDNA3PvuII, respectively.
HEK293T cell cotransfection
Cells were generally cotransfected by LipoD reagent, ac-
cording to Manufacturer’s instructions. Where not other-
wise specified, aliquots of 106 cells were cotransfected by
0.75 g of a ncRNA cofactor-expressing plasmid, 1.25 g
of an apofactor (or a control)-expressing plasmid and 0.25
g of pcDNA3PvuII-EGFP (see above), as internal con-
trol.
In specific cases (as highlighted in legends to figures),
cells were cotransfected by Lipofectamine 3000 reagent, ac-
cording to manufacturer’s instructions. Here two rounds of
cotransfection were performed, at a 12-hour interval. In
each round, where not otherwise specified, aliquots of 106
cells were cotransfected by 0.95 g of ncRNA cofactor-
expressing plasmid and 1.60 g of apofactor (or control)-
expressing plasmid.
Recombinant lentivirus production
Recombinant third generation self-inactivating (SIN)
lentiviruses were produced and titrated as previously
described (34).
Off-target gene selection
ncRNA bait sequences were blasted against human and
murine genomes byBlast software (accessible at http://blast.
ncbi.nlm.nih.gov and run online with the following pa-
rameters: blastn, ‘for somewhat similar sequences’; expect
threshold: 40; word size: 7; max matches in a query range :
0; match/mismatch scores, 2, -3; gap costs: existence 2, ex-
tension 2; filter low complexity regions: no; filter species-
specific repeats: no). Homologous modules found by Blast
were then prioritized and selected, based on their length
(between 50 and 110 bp), gap density (<20%) and iden-
tity (>70%). Selected modules were subsequently mapped
to the transcriptome, using theUCSCGenome browser (ac-
cessible at http://genome.ucsc.edu; assemblies mm10 and
hg19) and the Ensemble-GENCODE track (accessible at
http://www.ensembl.org). Lastly, they were filtered on the
basis of their distance from transcriptional start-site (TSS)
of potential off-target genes (from−0.5 kb to +0.5 kb). The
results are summarized in Supplementary Tables S5 and S6.
RNA profiling
Total RNA was extracted from cells using TRIzol Reagent
(Invitrogen) according to manufacturer’s instructions.
Agarose gel electrophoresis and spectrophotometric mea-
surements (NanoDrop ND-1000) were employed to esti-
mate its concentration, quality and purity.
At least 0.5g of total RNA from each sample was retro-
transcribed by SuperScriptIIITM (Invitrogen) in the pres-
ence of random hexamers, according to the manufacturer’s
instructions. 1/100 of the resulting cDNA was used as sub-
strate of any subsequent qPCR reaction. Limited to the in-
tronless amplicons, prior to the retrotranscription, RNA
preparations were treated by DNAseI (2U/g of RNA)
1 h at 37◦C, and processed by RNeasy Mini Kit (Qia-
gen). Next, negative control PCRs were run on RT− cDNA
preparations. In general, PCR reactions were performed by
the SsoAdvanced SYBRGreen SupermixTM platform (Bio-
rad), according to manufacturer’s instructions. For each
transcript under examination and each sample, cDNA was
PCR-analyzed in technical triplicate, against absolute stan-
dards, and average results calculated. Averages were nor-
malized againstGapdh and further normalized against con-
trols. Experiments were performed at least in biological trip-
licate and analyzed by Student’s t-test. Oligos were as in
Supplementary Table S3.
ChIP-qPCR
The chromatin immunoprecipitation quantitative poly-
merase chain reaction assays (ChIP-qPCRs) were per-
formed on chromatin extracted from HEK293T cells (case
NAP22) or neural cell cultures (case Emx2). Cells were
transfected with constitutive expression plasmids (case
NAP22) or acutely infected with bio-active and control
lentiviruses (case Emx2), similar to transactivation assays.
Then, they were kept in culture for 72 and 96 h, respectively.
ChIP analysis was performed according to theMAGnifyTM
Chromatin Immunoprecipitation System protocol (Invitro-
gen), with minor modifications.
For each ChIP assay, chromatin from 106 cells was fixed
by 1% formaldehyde, for 10 min at RT. After cell lysis, fixed
chromatin was sonicated by a Soniprep 150 apparatus (on
ice; 5 s ON, 55 s OFF; oscillation amplitude five microns;
four cycles) into ∼600 bp fragments. Sonicated chromatin
was immunoprecipitated for 2 h at 4◦C, by 1.5 g of an
-HA rat antibody (clone 3F10, Roche), 2.5 g of an -
RNApolII mouse antibody (clone 4H8, Abcam), or 2.5 g
of murine IgG (Invitrogen), in a final volume of 100 l.
Immunoprecipitated DNA was purified according to the
manufacturer’s instructions. Lastly, 1/30 of each immuno-
precipitated (IP) DNA sample (case -HA-IP) or 1/60 of
it (case -RNApolI-IP and IgG-IP controls) were ampli-
fied by qPCR. For each sample, qPCRs were performed in
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technical triplicate. Averages were normalized against input
chromatin and further normalized against NMHV/MF6-
øor NMHV/MF2-øcontrols, in case of NAP22 and Emx2
tests, respectively. Experiments were performed at least in
biological triplicate and analyzed by Student’s t-test. Oligos
were as in Supplementary Table S4.
Immunofluorescence
HEK293T cells, naive or lipofected with LV NMHV or
LV NMHV/pcDNA3PvuII-MF6-NAP22, were grown
on poly-L-lysine coated glass coverslips in 12 multiwell
plates, fixed with 4% paraformaldehyde (PFA) for 20 min
at 4◦C and then washed three times in 1X PBS. Lentivirus-
transduced, floating neural precursor aggregates were gen-
tly trypsinized to single cells and left to attach 1 h at 37◦C
to poly-L-lysine (200 g/l) coated SuperFrost Plus micro-
scope slides (Menzel-Glaser). Here they were fixed by 4%
PFA for 20 min at 4◦C and washed three times in 1X PBS.
In all cases, immunofluorescence was performed as pre-
viously described (6). The following primary antibodies
were used: anti-HA, rat clone 3F10 (Roche #12158167001),
1:500; anti-beta-actin, mouse clone AC-15 (Sigma #A3854,
1:1000); anti H3K9me3, rabbit polyclonal (Invitrogen
#P7N49–1008), 1:200; anti-Tubb3, mouse clone Tuj1 (Co-
vance #MMS-435P), 1:1000. Secondary antibodies were
conjugates of Alexa Fluor 488, and Alexa Fluor 594 (In-
vitrogen), used at 1:600.
HA, beta-actin and H3K9me3 immunofluorescences
were photographed on a Nikon Eclipse TI microscope,
equipped with a 40X objective and a Nikon C2 confocal
system. For each sample, Z-stacks of 6, 0.5m-spaced opti-
cal sections, flattened and averaged, were shown. Tubb3 im-
munofluorescences were photographed on a Nikon Eclipse
TS100 fluorescence microscope equipped with a DS-
2MBWC digital microscope camera with a 20X objective.
For each independent biological replicate, at least six fields,
corresponding to at least 1500 cells, were analyzed by an
operator blind of cells ‘genotype’. Images were processed
by Adobe Photoshop CS2 softwareTM. DAPI stained nuclei
images were counted with ImageJ Cell Counter plug-in.
Western blotting
Western analysis was performed according to standard
methods. Total cell lysates in CHAPS buffer were quanti-
fied by BCA protein assay kit (Fisher Scientific # 10678484)
and denatured at 95◦C for 5 min, prior to loading. Fifty
microgram of proteins was loaded per each lane and was
run on a 12% acrylamide −0.1% SDS gel. NAP22 was de-
tected by a primary rabbit anti-BASP1 polyclonal antibody
(Sigma #SAB2107478), used at 1:2500, and a secondary
HRP-conjugated anti-rabbit antibody (LifeTech # 32260),
used at 1:2000. As previously reported (43), under these
conditions NAP22 gives rise to a 50kDa dimer band. ACT
was detected by a peroxydase C-conjugated mouse mono-
clonal antibody (Sigma # A3854), used 1:10 000. NAP22
and ACT were sequentially revealed by an ECL kit (GE
Healthcare # GERPN2109). Images were acquired by an
Alliance LD2–77.WL apparatus (Uvitec, Cambridge) and
analyzed by Adobe Photoshop CS2 softwareTM and Mi-
crosoft Excel 11 softwareTM.
Statistical analysis
Each ‘biological replicate’ included cells pooled from at
least two independent wells/petri dishes. Numbers of bi-
ological replicates analyzed in each experiment are shown
under the corresponding graphs. Each biological replicate
was scored at least in technical triplicate. Data were normal-
ized as reported in figure legends, averaged and statistically
evaluated by Student’s t-test (unpaired, one-tail). Variabil-
ity was graphically shown by standard error of mean bars.
RESULTS
Upregulation of endogenous genes by artificial, non-
CRISPR, RNA-programmable transactivators
To overactivate our GOIs by a programmable device, we
first assembled a chimeric cDNA encoding for a novel
polypeptidic apo-transactivator, NMHV (Figure 1A). This
included anRNAbinding domain (RBD) as well as a trans-
activating domain (TAD). The former corresponds to the
V75E;A81Gmutant version of the bacteriophageMS2 coat
protein, with a low tendency to aggregate as well as an abil-
ity to bind its mRNAwith high affinity (25). The latter con-
sisted of three tandemly arranged F-type domains from the
VP16 protein of the herpes simplex virus (44). To target the
apo-transactivator to the cell nucleus, RBD was preceded
by two copies of the SV40-T protein nuclear localization sig-
nal (NLS) (45). To allow immunodetection of the resulting
polypeptide, a monomeric A influenza virus hemagglutinin
tag (HA) (46) was interposed between RBD and TAD.
Then, for each GOI we built the DNA copy of a dedi-
cated non-coding RNA cofactor (Figure 1A). This included
a hexameric,MS2 coat protein-binding stem-and-loopmoi-
ety (26,27) (MF6) and a mid-sized (around 120 bases long),
gene-specific RNA bait, complementary to a region near
the GOIs TSS and co-oriented with its mRNA.
As a proof of principle, we decided to test our device in
HEK293T cells, on three genes, FMR1,NAP22 andNRGN,
robustly expressed by these cells (http://webserver.mbi.ufl.
edu/∼shaw/293.html).We built the cDNAs encoding for the
NMHV apo-transactivator and the MF6-containing cofac-
tors specific for these genes (Figure 1C and Supplemen-
tary Table S1). We cloned them into RNA polymerase II
(RNApolII) expression vectors, downstream of the consti-
tutive Pgk1 and CMV promoters, respectively. Next, we as-
sessed the capability of the NMHVpolypeptide to enter cell
nuclei (Figure 1B) and we set up a DNA delivery protocol,
suitable to cotransfect a large fraction of HEK293T cells
in the presence of limited signs of toxicity (Supplementary
Figure S1).
Later, we co-delivered NMHV, MF6-FMR1, MF6-
NAP22 and MF6-NRGN plasmids (as well as their con-
trols) to HEK293T cells, in different combinations. After
three days, the transfected cells were profiled for the three
GOIs by qRTPCR (Figure 1C–F). Each NMHV/ncRNA
cofactor pair consistently stimulated the corresponding
GOI. Upregulation was 47±18% for FMR1 (P < 0.030),
83±16% for NAP22 (P < 0.004) and 25±4% for NRGN
(P < 0.014) (Figure 1D–F). Conversely, overexpression of
the three ncRNA cofactors in the absence of NMHV did
not elicit any significant effect (Figure 1D–F) and the re-
 at Sissa on N
ovem
ber 27, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
7854 Nucleic Acids Research, 2015, Vol. 43, No. 16
 at Sissa on N
ovem
ber 27, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 16 7855
Figure 1. Design of the ribo-transactivator and its proof-of-principle validation. (A) Structure of the NMHV apo-activator and its RNA cofactor. NMHV
includes: NLS2, nuclear localization signal 2x; RBD, MS2 RNA-binding domain; HA, hemagglutinin epitope and TAD, VP16-related transactivator
domain, 3x. The RNA cofactor includes: MF6, MS2-high affinity, stem-and-loop finger, 6x; and ‘bait’, short, target gene specific, RNA tag. GOI is the
GOI. (B) Subcellular distribution of NMHV in HEK293T cells, in the presence or in the absence of its MF6-NAP22 RNA cofactor, as revealed by anti-
HA immunofluorescence. Beta-actin and H3K9me3 distributions, cytoplasmic and nuclear, respectively, are also shown, as references. (C) Schematics of
human FMR1, NAP22 and NRGN loci, with natural transcripts, artificial baits and diagnostic amplicons used in this study. Nucleotide numbering refers
to UCSC-hg19. Color code: blu, DNA; green, sense-oriented RNA; red, antisense-oriented RNA. (D–F) Upregulation of FMR1, NAP22 and NRGN
mRNAs in HEK293T cells cotransfected with NMHV- and MF6-bait-encoding plasmids, as evaluated 72 h post-transfection. Pgkp1-EGFP (‘EGFP’)
and MF6-øplasmids were used as controls. Results were normalized against GAPDH and further normalized against the EGFP/MF6-øcombination.
(G, H) Upregulation of NAP22 protein by NMHV/MF6-NAP22. (G) Western blotting of NAP22 in HEK293T cells, four days after transfection by
NMHV/MF6-NAP22 or EGFP/MF6-ø, via the ‘Lipofectamine 3000 protocol’. (H) Quantification of NAP22 protein detectable in (G). Results were
normalized against ACT and further normalized against the EGFP/MF6-øcombination. Numbers of biological replicates, n, are displayed under the
graphs. Bars represent s.e.m.’s.
placement of the VP16 domain by an EGFP moiety abol-
ished gene upregulation (Supplementary Figure S2). Inter-
estingly, NMHV and MF6-NAP22 delivery to HEK293T
cells also led to a robust upregulation of NAP22 protein
(5.77±2.03-fold, P < 0.039, n = 3.3; see Figure 1G and H).
Remarkably, gene transactivation was specific. In fact,
each NMHV/ncRNA pair, while stimulating the corre-
sponding GOI, did not affect the other two genes (Supple-
mentary Figure S3). Moreover, selected genes sharing ex-
tensive homologies with the three GOIs in the surroundings
of their TSSs (Supplementary Table S5) were not affected
(Supplementary Figure S3). Transactivation did not spread
along the chromosome far from the intended bait target
(Supplementary Figure S4a). Conversely, it was restricted to
transcription units having their TSSs located in the 5′ and 3′
surroundings of such target (Figure 1C–E and Supplemen-
tary Figure S4b). Interestingly, the outcome of the manip-
ulation depended on bait orientation. While sense-oriented
RNA baits consistently supported NMHV-dependent GOI
transactivation (Figure 1C–F and Supplementary Figure
S4b), the antisense-oriented ones often failed to achieve this
effect (Supplementary Figure S4c).
To corroborate these findings and explore mechanisms
mediating transactivation, we monitored the level of
NAP22-pre-mRNA in HEK293T cells cotransfected with
NMHVand, alternatively,MF6-NAP22 or its negative con-
trol. [Here, to ease the detection of consequences of our
manipulations, we employed a further optimized trans-
fection protocol (Supplementary Figure S5)]. We found
that, upon delivery of NMHV and MF6-NAP22, the qRT-
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PCR signal corresponding to distinct regions of NAP22-
pre-mRNA was differentially affected. This signal was un-
changed across the splice donor site, while it was upregu-
lated by +41±4% (P < 0.032, n = 4.4) closer to the splice
acceptor site (Figure 2A and B).
Moreover, we evaluated the enrichment of NAP22 chro-
matin for select transcription effectors. We employed two
antibodies, recognizing the HA epitope and the RNApoIII
carboxyterminal domain. As for anti-HA ChIP, MF6-
NAP22 expression enriched the region immediately down-
stream of the bait target (Figure 2A) by 5.5±2.0-fold, com-
pared to MF6-ø(P < 0.039, n = 3.3) (Figure 2C). With
the same antibody, no enrichment was observed for chro-
matin of SLC4A2 (Figure 2C), a potential off-target of
MF6-NAP22 (Supplementary Table S5). Concerning anti-
RNApolII-ChIP, no change of the IP fraction was detected
in the region between theNAP22-bait target and theNAP22
splice donor. However, a moderate statistically significant
enrichment was observed at three more distal sites, by the
5′ and 3′ ends of the intron (+29±7%, P < 0.005, n = 4.4;
+32±2%, P < 0.023, n = 3.3 and +16±8%, P < 0.051, n
= 3.4; respectively; see Figure 2A, D and Supplementary
Figure S6).
All this suggests that, in the presence of theMF6-NAP22
cofactor, NMHV specifically binds to the surroundings of
NAP22-TSS. In turn, this seems to promote the progression
of RNApolII from the region immediately downstream of
the TSS toward the 3′ end of the gene and results in in-
creased transcription.
Specific upregulation of brain patterning genes in pallial
precursors by dedicated RNA-programmable transactivators
and its biological consequences
Encouraged by these results, we decided to test the porta-
bility of this strategy to a gene mastering cortico-cerebral
histogenesis, in an established in vitro model of this pro-
cess. We stimulated the embryonic patterning gene Emx2 in
high-density, primary cultures of murine, cortico-cerebral
precursors. Due to poor transfectability of these cells, we
moved to lentiviral vectors. As the hexameric MF6 moi-
ety resulted unstable in our lentiviral backbone (42), we re-
placed it by its monomeric MF1 version. ToMF1 we added
an Emx2-specific bait, obtaining the MF1-Emx2 cofactor.
We co-delivered lentiviruses encoding for NMHV, MF1-
Emx2 and their controls to Emx2-expressing (47), murine
embryonic day 12.5 (E12.5) pallial precursors, in different
combinations. Each virus was administered at a multiplic-
ity of infection (moi) of 10, which is sufficient to transduce
the almost totality of neural precursors, regardless of their
rostro-caudal identity (see Supplementary Figure S4 of (34)
and Supplementary Figure S7 of the present paper). Four
days later, infected cells were profiled for Emx2-mRNA by
qRTPCR (Figure 3A). Compared to controls, coexpression
of NMHV and MF1-Emx2 upregulated Emx2 by 16% (P
< 0.002, n = 9.7). Neither NMHV nor MF1-Emx2 alone
elicited any significant effect (Figure 3B). Moreover, com-
pared to uninfected cells, co-infection of precursors with
both control viruses was ineffective (+2.4%, with P < 0.36
and n = 5.6, Supplementary Figure S8).
It has been reported that upregulation of Emx2 in pal-
lial precursors slows down their neuronal differentiation
(6,30,33). To assess biological relevance of the small Emx2
upregulation elicited by NMHV andMF1-Emx2, we evalu-
ated the frequencies of cells expressing Tubb3 (an early neu-
ronal postmitoticmarker) within engineered neural cultures
(Figure 3C, D and Supplementary Figure S9). Compared
to controls, NMHV and MF1-Emx2 halved the frequency
of Tubb3+ cells (P < 10−6, with n = 10.10), meaning that
gene upregulation obtained by our strategy, albeit small,
can yield robust biological effects.
We suspected that the limited Emx2 upregulation elicited
could be due to suboptimal interaction between the apo-
transactivator and its ncRNA cofactor. Therefore, we tried
to improve performances of our device, addressing this
issue in two different ways. First, it has been reported
that RNAs containing increasing numbers of MS2-binding
stem-and-loop fingers interact with the MS2 coat pro-
tein in a progressively stronger way (48). Therefore, we re-
placed the monomeric-finger MF1-Emx2 cofactor by its
dimeric-finger MF2-Emx2 derivative and assessed the per-
formance of such derivative, paired with NMHV. Interest-
ingly, this device increased Emx2-mRNA by about 40%
(P < 0.005, n = 5.4), while MF2-Emx2 alone did not
elicit any significant effect (Figure 3E). Second, we hy-
pothesized that non-optimal apo-transactivator/RNA co-
factor ratios might jeopardize the outcome of the sys-
tem, because of defective holo-transactivator formation and
possible dominant-negative effects. So we modulated the
LV NMHV/LV MF2-Emx2 moi’s ratio, while keeping the
total moi fixed. When this ratio equaled 3:1, Emx2-mRNA
was increased by 55% (P < 0.002, n = 3.3) (Figure 3F).
To assess if MF2-Emx2/NMHV-dependent stimulation
was restricted to Emx2, we monitored the expression lev-
els of six other genes (Pax6, Hes6, Sip1, Couptf1, Nf1a
and Lhx2), randomly chosen among those active in pallial
precursors (49), that were potentially accessible to exoge-
nous transactive complexes. None were affected, when neu-
ral cells were challenged by the best Emx2-transactivating
strategy described above (Supplementary Figure S10a).
Four additional genes (Arid1a, CachD1, Ptpn12 and Dvl3),
sharing extensive homologies with Emx2 in the surround-
ings of their TSSs (Supplementary Table S6), were nei-
ther affected (Supplementary Figure S10a). Notably, the
replacement of the original ncRNA bait with its reverse
complementary counterpart abolished Emx2 transactiva-
tion (Supplementary Figure S11a).
To corroborate these findings, we performed aChIP anal-
ysis. We immunoprecipitated chromatin of neural precur-
sors infected with LV NMHV and, alternatively, LV MF1-
Emx2 or its negative control, by an anti-HAantibody. Then,
we quantified the genomic region downstream of theEmx2-
bait by qPCR (Figure 3A). LV MF1-Emx2 expression en-
riched this region by 3.0±0.2, compared to LV MF1-ø(P<
0.0005, n = 3.3). No enrichment was conversely observed
for the chromatin of three potential LV MF1-Emx2 off-
targets, Ptpn12, CachD1 and Dvl3 (Figure 3G and Supple-
mentary Table S6). This suggests that NMHV physically
and specifically interacts with the Emx2 locus in living cells,
depending on the Emx2-bait, and possibly stimulates Emx2
transcription.
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Figure 2. Mechanisms underlying NAP22 transactivation in HEK293T cells. (A) Schematics of the NAP22 locus with NAP22-bait and diagnostic ampli-
cons employed for the analysis. (B) Modulation of NAP22-pre-mRNA in NMHV/MF6-NAP22-expressing cells, evaluated by intronic qRTPCR. Results
were normalized against GAPDH and further normalized against the EGFP/MF6-øcombination. (C) Recruitment of NMHV at NAP22 promoter in
NMHV/MF6-NAP22-expressing cells, evaluated by anti-HA-ChIP/qPCR. The potential NAP22-offtarget SLC4A2 was used as a specificity control. (D)
RNApolII binding at different sites of the NAP22 locus in NMHV/MF6-NAP22-expressing cells, evaluated by anti-RNApolII-ChIP/qPCR. In (C, D)
results were normalized against input chromatin and further normalized against the NMHV/MF6-øcontrol. Noticeably, in (B, D) cells were transfected
by the ‘Lipofectamine 3000 protocol’. In (B-D) cell culture timing was as described in Figure 1. Numbers of biological replicates, n, are displayed under
the graphs. Bars represent s.e.m.’s.
 at Sissa on N
ovem
ber 27, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
7858 Nucleic Acids Research, 2015, Vol. 43, No. 16
Figure 3. NMHV-mediated transactivation of Emx2 in murine, embryonic cortico-cerebral precursors and its molecular and biological correlates. (A)
Schematics of the murine Emx2 locus, with natural transcripts, artificial baits and diagnostic amplicons used in this study. Nucleotide numbering refers
to UCSC-mm10. Color code: blu, DNA; green, sense-oriented RNA; red, antisense-oriented RNA. (B)Emx2-mRNA upregulation in precursors infected
by NMHV- and MF1-Emx2-encoding lentivectors. EGFP and MF1-øviruses were used as controls. Results were normalized against Gapdh and further
normalized against the EGFP/MF1-øcombination. (C) Reduced frequency of cells immunopositive for the neuron-specific Tubb3 marker, in cultures of
NMHV/MF1-Emx2-overexpressing precursors. Results were normalized against EGFP/MF1-øcontrols. (D) Examples of aTubb3 immunofluorescences
referred to in (C). (E) Enhancing Emx2 transactivation by improving the RNA cofactor structure. The assay was run similar to Figure 2A, replacing the
monomeric-finger ‘MF1-bait’ cofactor by its dimeric-finger ‘MF2-bait’ derivative. (F) Enhancing Emx2 transactivation by increasing the m.o.i. ratio of
NMHV- and MF2-Emx2-encoding lentiviruses. The best results were obtained by an NMHV/MF2-Emx2 ratio of 3:1. (G)Emx2 promoter enrichment
in chromatin of NMHV/MF1-Emx2-overexpressing precursors, immunoprecipitated by an anti-HA antibody. Results were normalized against input
chromatin and further normalized against the NMHV/MF1-øcontrol. Promoters of potential Emx2-offtargets Ptpn12, CachD1 and Dvl3 were used as
specificity controls. In all cases (B-G), cortico-cerebral cells were dissociated from E12.5 embryos, acutely infected, cultured for 96 h and finally analyzed.
Throughout the figure, lentiviral multiplicities of infection (moi’s) and numbers of biological replicates, n, are displayed under the graphs. Bars represent
s.e.m.’s.
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To generalize these results, we built a ncRNA cofactor
specific for another key gene involved in brain patterning,
Foxg1 (Figure 4A). Coexpression of NMHV and MF1-
Foxg1 cofactor in murine pallial precursors upregulated
Foxg1 by 23% (P < 0.002, n = 3.3) (Figure 4B). This led to
a pronounced decrease of newborn, Tubb3+ neurons gen-
erated by the engineered culture (about −70%, with P <
0.0004 and n= 3.3) (Figure 4C andD). Transactivation was
restricted to the intended transcription unit. Neither the
structurally unrelated Emx2 nor the Foxg1-cis-associated
AK158887 and 3110039M20Rik-001 units were affected
(Supplementary Figures S10b and S11b).
Lastly, to better define the prospective scope of applica-
tion of our device, we considered its effectiveness in correla-
tion to the baseline expression level of the GOI. The ques-
tion arose since our ncRNA cofactors did not harbor long
polypurine/polypyrimidine tracts required for RNA:DNA
triple helix formation (50). For this reason, the interaction
of these cofactors with chromatin could require a transcrip-
tionally active conformation, prone to alternative mech-
anisms of ncRNA tethering (such as ncRNA:DNA het-
eroduplexing or ncRNA docking to nascent RNAs). To
preliminarily address this issue, we delivered our best per-
forming Emx2- and Foxg1-promoting protocols to neural
precursors taken from two regions of the embryonic neu-
ral tube which do not express these two genes, rhombo-
spinal tract (47) and mesencephalon (51), respectively. As
expected, GOI-mRNA levels remained extremely low as
compared to cortico-cerebral precursors. No gene upregu-
lation was elicited at all (Figure 5A–C).
Shortening the baits and assessing mismatch tolerance of our
device
To further optimize our device, we shortened the RNA bait
in charge of recognizing the GOI. This would minimize off-
target risks and it would make chemical synthesis of baits
for therapeutic applications easier. We replaced the NAP22
and FMR1.1 baits, sense-oriented and approximately 120b
long, with their respective 5′ and 3′ halves (.60L and .60R,
respectively, see Supplementary Table S1), and assayed the
corresponding MF6-containing cofactors with the NMHV
apofactor, inHEK293T cells. All four baits were able to sup-
port transactivation of the intended target genes (Figure 6A
and B).
To confirm this result, additional tests were run on
the Emx2-activating device, in cortico-cerebral precursors.
Here, reducing the ncRNA bait from 179 to 60 bases (Sup-
plementary Table S1) did not jeopardize device activity,
which was slightly increased (Figure 6C). Further halving
of bait length reduced such activity to hemi-maximal val-
ues (Figure 6C), suggesting that 60 base-long baits could be
a satisfactory tool for gene stimulation.
Finally, to further confirm the specificity of our device,
we mutagenized the most effective ‘.60-type’ bait referred
to above, NAP22.60L, and assessed the performances of the
resulting MF6 chimaeras. Replacement of 30% of the orig-
inal bases by mutant ones, distributed in one to four equi-
spaced mismatch modules, fully suppressed NAP22 trans-
activation (Figure 6D and Supplementary Table S7). Con-
versely, replacement of 15% of these bases resulted into a
more articulated pattern. Transactivation was still observed
when the baits included fully homologous modules of ≥18
bases. It was completely abolished as the length of these
modules fell below 14 (Figure 6E and Supplementary Ta-
ble S7).
DISCUSSION
Here we describe a novel ribonucleoproteic transactivator
able to stimulate expression of endogenous genes ad libitum.
This device was able to enter the nucleus and interact with
the GOI chromatin through its RNA cofactor. By means
of it, we specifically upregulated five independent genes, in
cell lines as well as in primary cultures of murine pallial pre-
cursors. Such upregulation was small. However, it was suffi-
cient to trigger an appreciable biological effect. Remarkably,
activity of this device was restricted to cells where the GOI
is normally transcribed. Finally, it was possible to improve
this transactivator, by optimizing the interaction between
polypeptidic and RNA components of it as well as reduc-
ing the size of the GOI-specific RNA bait.
The expression gains we observed primarily in HEK293T
cells were +47±18% for FMR1, +83±16% for NAP22 and
+25±4% for NRGN. We are aware that random fluctua-
tions of cell cultures upon experimental manipulation and
trivial off-target effects could contribute to them. How-
ever, a high bait-target homology was needed to get mRNA
upregulation (Supplementary Figures S3, S10 and Figure
6). Moreover, results were consistently reproducible over
a number of biological replicates (e.g.: MF6-NAP22.60L-
dependent NAP22 upregulation, shown in Figure 6A,D,E,
and MF1-Emx2-dependent Emx2 upregulation, in Figure
3B and Supplementary Figure S11a). All that suggests that
these expression gains were largely due to specific gene stim-
ulation.
Notably, the results referred to above were obtained
upon cotransfection of about only one-third of the total
HEK293T cell population (Figure 1 and Supplementary
Figure S1). Likewise, the best upregulation elicited in neural
precursors (+55±4%, for Emx2) was detected in a cell pop-
ulation infected at moi’s of 15 and 5 (Figure 3F) and there-
fore cotransduced at only 75% (see Supplementary Figure
S3 of (34)). When the transfected HEK293T cell fraction
was doubled (thanks to an optimized protocol), NAP22
and NRGN upregulation increased up to +143±17% and
+38±12%, respectively (Supplementary Figure S5).
However, incomplete cell population transduction could
not be the only cause of limited gene expression gain and
additional issues likely contributed to it. Among them there
is the poor stability of our apoenzyme/coenzyme complex.
In fact, better performances were elicited, as the number
of MF fingers included into the RNA cofactor increased
(Figures 1D–F, 3B,E and 4B). In addition, substantial ben-
efits could be achieved by appropriately modulating the
apofactor/cofactor ratio (Figure 3F). Second, the limited
power of our device could reflect suboptimal interaction be-
tween the transactivator and its target gene. In this respect, a
stronger transactivation might be achieved by targeting the
same gene with multiple baits. On the other hand, the possi-
bility of implementing amulti-gene overexpression program
by a polygenic bait should be explored.
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Figure 4. NMHV-mediated transactivation of Foxg1 in murine, embryonic cortico-cerebral precursors and its biological correlate. (A) Schematics of
the murine Foxg1 locus, with natural transcripts, artificial baits and diagnostic amplicons used in this study. Nucleotide numbering refers to UCSC-
mm10. Color code: blu, DNA; green, sense-oriented RNA. (B)Foxg1-mRNA upregulation in precursors infected by NMHV- and MF1-Foxg1-encoding
lentivectors. EGFP and MF1-øviruses were used as controls. Results were normalized against Gapdh and further normalized against the EGFP/MF1-
øcombination. (C) Reduced frequency of cells immunopositive for the neuron-specific Tubb3 marker, in cultures of NMHV/MF1-Foxg1-overexpressing
precursors. (D) Examples of aTubb3 immuno-fluorescences referred to in (C). In all cases (B–D) time-frame of the experiments as well as representation
of moi’s and statistical parameters are as in Figure 3.
Figure 5. Lack of responsivity to Emx2- and FoxG1-specific ribo-transactivators by neural precursors of non-cortico-cerebral origin. (A) Unchanged
Emx2-mRNA levels in E10.5 rhombo-spinal precursors, infected by NMHV- and MF2-Emx2-encoding lentiviruses or EGFP- and MF2-øcontrols. (B)
Unchanged FoxG1-mRNA levels in E10.5 mesencephalic precursors, infected by NMHV- and MF1-FoxG1-encoding lentiviruses or EGFP and MF1-
øcontrols. In both (A) and (B), transactivation of the two genes in E12.5 cortico-cerebral precursors is shown, as a positive control. Moreover, in both
cases, results were normalized againstGapdh and further normalized against E12.5 cortico-cerebral precursors treated by EGFP/MF2-øand EGFP/MF1-
øcombinations, respectively. Time frame of the experiments as well as representation of moi’s and statistical parameters is as in Figure 3. (C) Idealized
representation of the murine E10.5 neural tube. cx, cerebral cortex; m, mesencephalon; rs, rhombo-spinal tract.
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Figure 6. Consequences of RNA-bait shortening and mutagenesis. (A-C) Comparison of NMHV-dependent gene activation driven by select ‘primary’
baits, NAP22 (A), FMR1.1 (B) and Emx2-S (C), and ‘secondary’ baits obtained by heminested shortening of the former ones. (D, E) Full or partial
suppression of NMHV-dependent NAP22 transactivation driven by the NAP22.60L bait, upon replacement of 30% (D) or 15% (E) of its original bases
by mutant ones. Mutant bases were distributed in up to four (D) and up to 10 (E) equispaced mismatching modules, as shown in top panels (sequences
of mutant baits are reported in Supplementary Table S7). Results were normalized against GAPDH (A, B, D, E) and Gapdh (C) and further normalized
against EGFP/MF6-ø(A, B, D, E) and EGFP/MF2-ø(C) control samples. Time frame of the experiments as well as representation of moi’s and statistical
parameters was as in Figures 1 (A, B, D, E) and 3 (C).
Even if Emx2 and Foxg1 upregulation obtained in this
study was <2-fold, it was sufficient to robustly change the
behavior of neural precursors (Figures 3C,D and 4C,D).
This occurred in dorsal telencephalic (i.e. pallial) precur-
sors, kept as high-density floating cultures under growth
factors. These conditions do not affect precursors’ posi-
tional identity (52,53), stimulate their mitotic activity and
largely recreate the complexity of cell–cell interactions char-
acterizing proliferative layers of the developing brain (34).
The responsivity that neural cells showed to even subtle
variations of gene expression levels was not surprising. In
fact, similar findings were previously reported forEmx2 and
other genes involved in brain patterning (6,54,55). The in-
hibition of neuronal differentiation triggered by Emx2 and
Foxg1 upregulationmight be exploited to enlarge the prolif-
erating neural pool, namely a result of obvious therapeutic
interest (34).
Gene stimulation obtained by our device was specific, in
at least three key aspects. First, it required the coexpression
of both the NMHV apofactor and the GOI-cofactor. Re-
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moval of NMHV or replacement of the NMHV-VP16 moi-
ety by an EGFP polypeptide fragment abolished it (Figures
1D–F, 3B,E,F, 4B and Supplementary Figure S2). [Actually,
two baits out of eight working ones, FMR1.2 and NAP22-
AS, upregulated the corresponding genes to some extent,
even in the absence of the apofactor. However, in these two
cases, gene upregulation was far more pronounced upon
further NMHV expression (Supplementary Figure S4b and
c). Moreover, NMHV reversed gene-downregulation in-
duced by two antisense baits, MF6-NRGN-AS and MF1-
Emx2-AS (Supplementary Figures S4c and S11a, respec-
tively)].
Second, GOI stimulation required high homology be-
tween the RNA bait and its intended target sequence. Po-
tential off-target genes, suitable to be transcribed and/or
provided with partial homology to our GOIs in the sur-
roundings of their TSSs, were not affected (Supplementary
Figures S3 and S10 and Supplementary Tables S5 and S6).
The RNA bait could be shortened up to 60 bases, in the
absence of adverse effects (Figure 6A–C). Mutagenizing
the 60-bp-long NAP22 bait by 30% fully abolished NAP22
stimulation (Figure 6D and Supplementary Table S7). As
the mutagenesis rate was lowered to 15%, transactivation
was detectable only when the bait included fully matching
modules longer than 17 bases (Figure 6E and Supplemen-
tary Table S7).
Third, the bait-dependent transactivating effect exerted
by NMHV was tightly restricted to the surroundings of the
bait target and depended on bait orientation. TSSs located
>1 kb far from the bait target were not affected (Supple-
mentary Figures S4a and S11b). Conversely, transcription
units having their 5′ ends <0.5 kb far from the bait target
displayed amore articulated behaviour.UponNMHVover-
expression, theywere generally stimulated by sense-oriented
baits (Figures 1C–G, 3A,B,E,F, 4A,B and Supplementary
Figure S4b), while variably responding to antisense ones
(Supplementary Figures S4c and S11a).
To summarize, as length, orientation and distance from
TSS of the RNA bait were properly tuned, our device ap-
peared to work specifically and reliably. As many as six pri-
mary baits out of six tested, 115–179 bases long, sense-
oriented and directed against TSS-proximal targets (Fig-
ures 1C–F, 3A,B,E,F and 4A,B, and Supplementary Figure
S4b), supported an appreciable and selective gene upregu-
lation. Moreover, the same happened for six more baits, ob-
tained from shortening of the primary ones (Figure 6A–C).
During the execution of this study, several groups
reported the successful creation of a novel RNA-
programmable transactivator type (18–23), originating
from domestication of Type II, bacterial CRISPR adaptive
immune system. Compared to CRISPR effectors, our
NMHV apofactor shows three substantial differences.
First, it is 7-fold smaller (24), which may facilitate its
artificial synthesis and delivery. Second, it is considerably
less powerful than CRISPR effectors (20). This may reflect
the helicase activity intrinsic to CRISPR molecules (56),
absent in ours. Third, CRISPR-DNA interactions are
not prevented by repressive epigenetic marks, such as
H3K27me3 (22) or 5meC (23,57), and CRISPR-stimulated
genes include silent transcription units (21,23) (our data
not shown). Conversely, our device only works with genes
already expressed at sustained levels (Figure 5). These last
two features obviously limit the general interest in our de-
vice. On the other side, they make it potentially suitable for
specific applications, such as rescue of haploinsufficiencies.
In theory, the best performing RNA-baits used in this
study, being co-oriented with the upregulatedmRNAs (Fig-
ures 1C–F, 3A,B,E,F, 4A,B and Supplementary Figure
S4b), might act as molecular decoys for possible antisense
transcripts. However, except one case (Supplementary Fig-
ure S4b), gene upregulation elicited by our RNA cofac-
tors generally required the presence of the bulky NMHV
apofactor (Figures 1D–F, 3B,E,F, 4B and Supplementary
Figure S2), which is at odds with the decoy hypothesis.
Moreover, the majority of our working RNA cofactors,
being co-oriented with their cognate mRNAs, cannot di-
rectly interact with them. This rules out any further possi-
bility of post-transcriptional regulation. On the other side,
ChIP data show that the NMHV polypeptide is recruited
to chomatin in aRNA-cofactor-dependent way (Figures 2C
and 3G).Moreover, the enrichment of 3′ regions of the GOI
for RNApolII arises (Figure 2D). Finally, upregulation of
mRNA is associated to increased levels of its pre-mRNA
precursor (Figure 2B). Altogether, these data suggest that
our device rather acts by promoting gene transcription.
We do not know how our transactivator recognizes its
target and promotes transcription. Concerning gene recog-
nition, should the RNA cofactor directly interact with
its cognate DNA, this would hardly occur via a triple
helix structure, as triple helix formation requires long
homopurinic-homopyrimidinic traits, absent in our baits
(50). Conversely, the RNA cofactor could bind to the
DNA template––previously unwound by the transcription
machinery––via Watson and Crick base pairing, leading
to D-loop formation. Alternatively, gene recognition could
be indirect, i.e. the RNA cofactor might be docked to
chromosomes via nascent antisense RNA molecules, still
tethered to the sense-TSS surroundings. Actually, anti-
sense transcripts spanning sense-TSSs were documented
at the NAP22, FMR1 and Emx2 loci, the most respon-
sive to NMHV/RNA-cofactor stimulation (Figures 1C–
F and 3A,B,E,F). Similar transcripts could have escaped
detection at the NRGN and Foxg1 loci, less responsive
to NMHV/RNA-cofactor, because of their lower abun-
dance (Figures 1C–F and 4A,B). Interestingly, docking
of ncRNA co-transactivators to nascent antisense RNAs
would nicely account for preferential requirement of sense-
oriented RNA baits to achieve gene transactivation (Sup-
plementary Figures S4c and S11a).
Regardless of the mechanism of chromatin recogni-
tion, RNA-mediated tethering of NMHV to 5′ TSS sur-
roundings might promote transcription by a variety of
VP16-dependent mechanisms (58–63). VP16 can promote
both transcription initiation and pre-mRNA elongation
(58). However, an antibody recognizingRNApolII enriched
the immunoprecipitate fromNMHV/MF6-NAP22-treated
cells for NAP22 intronic regions, but not for NAP22-TSS
surroundings (Figure 2D). This is puzzling. It could re-
flect the fact that the gain in RNApolII progression driven
by NMHV/MF6-NAP22 matched or exceeded the gain in
RNApolII recruitment at the TSS, resulting in no net in-
crease of RNApolII bound to the TSS region. No doubt,
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all these mechanistic aspects deserve further in-depth inves-
tigation.
In conclusion, here we described a novel programmable
transactivator, including a polypeptidic effector and an
RNA bait in charge of recognizing the intended target gene.
We provided a basic characterization of its functional prop-
erties. We preliminarily addressed molecular mechanisms
mediating its action. This device might be useful for some
specific applications. Presently, however, it is a simple pro-
totype, which still needs a substantial improvement of its
transactivation power as well as a better characterization of
its target specificity and mechanism of action. These issues
will be hopefully subject of a dedicated follow-up study.
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